Prostatype Genomics publishes year-end report for 2023

Prostatype Genomics AB today publishes its year-end report for the full year 2023, including the interim report for the second half of 2023. The full year-end report is attached and can also be downloaded from the company’s website, www.prostatypegenomics.com.

Summary of the second half of the year and the full year 2023

Second half of 2023, 1 July 2023 – 31 December 2023
• Net sales amounted to 908 TSEK (414)
• EBITDA (earnings before interest, taxes, depreciation, and amortization) amounted to -17,797 TSEK (-14,849)
• Cash flow from current operations amounted to -9,938 TSEK (-16,386)
• Total cash flow for the period amounted to -9,269 TSEK (2,677)
• Earnings per share amounted to -0.17 SEK (-0.71)

Full year 2023, 1 January 2023 – 31 December 2023
• Net sales amounted to 1,356 TSEK (683)
• EBITDA (earnings before interest, taxes, depreciation, and amortization) amounted to -37,372 TSEK (-26,785)
• Cash flow from current operations amounted to -29,138 TSEK (-27,704)
• Total cash flow for the period amounted to -8,793 TSEK (-8,840)
• Earnings per share amounted to -0.35 SEK (-1.27)

CEO Fredrik Persson comments:
“During the second half of 2023, Prostatype Genomics achieved significant progress in three important areas: continued scientific and clinical validation of the clinical benefit of Prostatype® for optimal treatment, establishment of our testing service in selected markets in Europe and Asia, and establishment of the testing service in the United States. We also note a continued sales increase in Europe and in Taiwan, although we are still at relatively low levels. 2024 is expected to become a transformative and highly value-creating year for the company, and it began with several achieved milestones at a rapid pace towards an expected market launch in the United States later this year.”

For more information, please contact:
Fredrik Persson, CEO
Telephone: +46 (0)73 049 77 01
Email: [email protected]

This disclosure contains information that Prostatype Genomics AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person above, on 2024-02-15, at 08:00 CET.